Since last year,
C-Reactive Protein is one of the most used biomarkers for inflammatory diseases and to monitor infection levels in relation to antibiotic treatment and usage. It represents a significant potential in a home-hospital context for patients at risk of getting serious infections.
The objective for Egoo health is to have a menu that contains the most critical biomarkers that makes it possible safely to monitor blood levels from home.
CEO,
"We are extremely pleased with the collaboration. Taking the first biomarker into trials is an important validation of the collaboration and has been done in record time. We expect the hospital trial to take 3-4 months, after which we will file for regulatory approval and clearance for sales and marketing. As previously communicated, following market clearance of 3 biomarkers including C-Reactive Protein, the first full year of sales from the collaboration in the Chinese market is estimated to be in the range of 100-200 MSEK" says Thomas Warthoe.
This information was submitted for publication, through the agency of the contact person set out above, at
For more information please contact:
Thomas Warthoe, CEO
tw@egoo.health
+45 21 63 35 34
https://news.cision.com/qlife-holding-ab/r/qlife-starts-clinical-trial-in-china-with-first-biomarker-on-egoo-health,c3993451
(c) 2024 Cision. All rights reserved., source